Stock Track | Bio-Rad Laboratories Soars 6.06% After Beating Q1 Earnings Expectations

Stock Track

May 02, 2025

Bio-Rad Laboratories (BIO) stock is soaring 6.06% in pre-market trading on Friday, following the release of its first-quarter 2025 earnings report that significantly exceeded analyst expectations. The company reported adjusted earnings of $2.54 per share, surpassing the mean expectation of $1.81 per share from seven analysts.

Despite a 4.2% year-over-year decline in revenue to $585.40 million, Bio-Rad still managed to outperform analyst predictions of $573.26 million. The company's Clinical Diagnostics Group showed resilience amid macroeconomic challenges, while the Life Science segment faced some headwinds, particularly in academia and biopharma research.

However, investors seem to be focusing on the positive aspects of the report, including the company's strong free cash flow of $96 million, up from $30 million in Q1 2024. Bio-Rad's innovative product launches and the upcoming acquisition of Stilla Technology are also likely contributing to investor optimism. The company has adjusted its 2025 guidance, now expecting non-GAAP, currency-neutral revenue to range from a decline of 1% to growth of 1.5%, reflecting ongoing market uncertainties.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1136422550"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136422550\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136422550?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 21:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136422550","market":"hk","top_or_hot":-1,"title":"Stock Track | Bio-Rad Laboratories Soars 6.06% After Beating Q1 Earnings Expectations","media":"Stock Track","content":"<p>Bio-Rad Laboratories (BIO) stock is soaring 6.06% in pre-market trading on Friday, following the release of its first-quarter 2025 earnings report that significantly exceeded analyst expectations. The company reported adjusted earnings of $2.54 per share, surpassing the mean expectation of $1.81 per share from seven analysts.</p>\n\n<p>Despite a 4.2% year-over-year decline in revenue to $585.40 million, Bio-Rad still managed to outperform analyst predictions of $573.26 million. The company's Clinical Diagnostics Group showed resilience amid macroeconomic challenges, while the Life Science segment faced some headwinds, particularly in academia and biopharma research.</p>\n\n<p>However, investors seem to be focusing on the positive aspects of the report, including the company's strong free cash flow of $96 million, up from $30 million in Q1 2024. Bio-Rad's innovative product launches and the upcoming acquisition of Stilla Technology are also likely contributing to investor optimism. The company has adjusted its 2025 guidance, now expecting non-GAAP, currency-neutral revenue to range from a decline of 1% to growth of 1.5%, reflecting ongoing market uncertainties.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bio-Rad Laboratories Soars 6.06% After Beating Q1 Earnings Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bio-Rad Laboratories Soars 6.06% After Beating Q1 Earnings Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-02 21:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bio-Rad Laboratories (BIO) stock is soaring 6.06% in pre-market trading on Friday, following the release of its first-quarter 2025 earnings report that significantly exceeded analyst expectations. The company reported adjusted earnings of $2.54 per share, surpassing the mean expectation of $1.81 per share from seven analysts.</p>\n\n<p>Despite a 4.2% year-over-year decline in revenue to $585.40 million, Bio-Rad still managed to outperform analyst predictions of $573.26 million. The company's Clinical Diagnostics Group showed resilience amid macroeconomic challenges, while the Life Science segment faced some headwinds, particularly in academia and biopharma research.</p>\n\n<p>However, investors seem to be focusing on the positive aspects of the report, including the company's strong free cash flow of $96 million, up from $30 million in Q1 2024. Bio-Rad's innovative product launches and the upcoming acquisition of Stilla Technology are also likely contributing to investor optimism. The company has adjusted its 2025 guidance, now expecting non-GAAP, currency-neutral revenue to range from a decline of 1% to growth of 1.5%, reflecting ongoing market uncertainties.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIO","symbol_name":"Bio Rad实验室","start_time":0,"source_url":"","article_id":"1136422550","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136422550","pubTimestamp":1746193882,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Bio-Rad Laboratories  stock is soaring 6.06% in pre-market trading on Friday, following the release of its first-quarter 2025 earnings report that significantly exceeded analyst expectations. The company reported adjusted earnings of $2.54 per share, surpassing the mean expectation of $1.81 per share from seven analysts.Despite a 4.2% year-over-year decline in revenue to $585.40 million, Bio-Rad still managed to outperform analyst predictions of $573.26 million. The company's Clinical Diagnostic","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIO":"Bio Rad实验室"},"translate_title":"股票赛道Bio-Rad Laboratories第一季度盈利超出预期后飙升6.06%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIO":1},"content_text":"Bio-Rad Laboratories (BIO) stock is soaring 6.06% in pre-market trading on Friday, following the release of its first-quarter 2025 earnings report that significantly exceeded analyst expectations. The company reported adjusted earnings of $2.54 per share, surpassing the mean expectation of $1.81 per share from seven analysts.\nDespite a 4.2% year-over-year decline in revenue to $585.40 million, Bio-Rad still managed to outperform analyst predictions of $573.26 million. The company's Clinical Diagnostics Group showed resilience amid macroeconomic challenges, while the Life Science segment faced some headwinds, particularly in academia and biopharma research.\nHowever, investors seem to be focusing on the positive aspects of the report, including the company's strong free cash flow of $96 million, up from $30 million in Q1 2024. Bio-Rad's innovative product launches and the upcoming acquisition of Stilla Technology are also likely contributing to investor optimism. The company has adjusted its 2025 guidance, now expecting non-GAAP, currency-neutral revenue to range from a decline of 1% to growth of 1.5%, reflecting ongoing market uncertainties.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}